Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Citius Pharmaceuticals, Inc. (CTXR), a Nevada corporation, filed this Current Report on Form 8-K on January 24, 2021, regarding a material definitive agreement and unregistered sale of equity securities. The transaction closed on January 27, 2021.
Key Financial Metrics
- Gross Proceeds: Approximately $20.0 million from the sale of 15,455,960 shares of common stock and warrants to purchase up to 7,727,980 shares.
- Net Proceeds: Approximately $18.4 million after deducting placement agent fees, expenses, and estimated offering costs.
- Placement Agent Fees: $1.4 million (7.0% of gross proceeds) plus $85,000 in non-accountable expenses paid to H.C. Wainwright & Co., LLC.
- Use of Proceeds: General corporate purposes, including pre-clinical and clinical development of product candidates, working capital, and capital expenditures.
Material Changes and Transaction Details
The company entered into a securities purchase agreement to sell unregistered securities at a purchase price of $1.294 per share and associated warrant. The warrants are exercisable immediately at $1.231 per share and expire five and one-half years from issuance. Additionally, the company granted the placement agent warrants to purchase up to 1,081,917 shares at an exercise price of $1.6175 per share. A registration rights agreement was executed to register the shares for resale.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to advance the clinical development of product candidates. The filing notes that representations and warranties in the purchase agreement are for the benefit of the parties and may apply different materiality standards than those viewed by stockholders. The securities were sold in reliance on exemptions from registration under Section 4(a)(2) and Rule 506 of the Securities Act of 1933.
Investor Verification Checklist
- Verify the dilution impact of the 15,455,960 new shares and the potential issuance of 7,727,980 shares upon warrant exercise.
- Confirm the specific allocation of the $18.4 million net proceeds between clinical trials and general working capital in subsequent filings.
- Review the full terms of the warrants (Exhibits 4.1 and 4.2) for adjustment provisions and exercise conditions.
- Monitor the filing of the registration statement for resale of the shares as required by the registration rights agreement.